Silence Therapeutics plc (SLNCF)
OTCMKTS
· Delayed Price · Currency is USD
0.9700
0.00 (0.00%)
May 8, 2025, 4:00 PM EDT
Silence Therapeutics Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2015 - 2019 |
|---|---|---|---|---|---|---|
Period Ending | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2015 - 2019 |
| Revenue | 43.26 | 31.64 | 21.66 | 16.81 | 7.48 | Upgrade
|
| Revenue Growth (YoY) | 36.71% | 46.12% | 28.82% | 124.73% | 2214.81% | Upgrade
|
| Cost of Revenue | 11.81 | 12.87 | 13.46 | 10.1 | 5.14 | Upgrade
|
| Gross Profit | 31.45 | 18.78 | 8.19 | 6.71 | 2.34 | Upgrade
|
| Selling, General & Admin | 26.88 | 26.22 | 25.68 | 27.09 | 19.09 | Upgrade
|
| Research & Development | 54.15 | 44.99 | 33.73 | 41.66 | 27.59 | Upgrade
|
| Other Operating Expenses | - | - | - | - | -2.04 | Upgrade
|
| Operating Expenses | 81.03 | 71.21 | 59.41 | 68.75 | 44.65 | Upgrade
|
| Operating Income | -49.58 | -52.43 | -51.22 | -62.03 | -42.3 | Upgrade
|
| Interest Expense | - | - | - | -0.01 | -0.02 | Upgrade
|
| Interest & Investment Income | - | - | - | 0.01 | 0.18 | Upgrade
|
| Currency Exchange Gain (Loss) | 0.65 | -2.64 | 1.29 | -0.06 | -7.06 | Upgrade
|
| Other Non Operating Income (Expenses) | 4.47 | 1.8 | 0.28 | - | - | Upgrade
|
| EBT Excluding Unusual Items | -44.46 | -53.27 | -49.65 | -62.09 | -49.21 | Upgrade
|
| Pretax Income | -44.46 | -53.27 | -49.65 | -62.09 | -49.21 | Upgrade
|
| Income Tax Expense | 0.85 | 0.96 | 0.69 | -8.73 | -4.77 | Upgrade
|
| Net Income | -45.31 | -54.23 | -50.33 | -53.36 | -44.44 | Upgrade
|
| Net Income to Common | -45.31 | -54.23 | -50.33 | -53.36 | -44.44 | Upgrade
|
| Shares Outstanding (Basic) | 46 | 37 | 32 | 30 | 27 | Upgrade
|
| Shares Outstanding (Diluted) | 46 | 37 | 32 | 30 | 27 | Upgrade
|
| Shares Change (YoY) | 24.69% | 15.21% | 8.58% | 8.78% | 8.85% | Upgrade
|
| EPS (Basic) | -0.98 | -1.46 | -1.56 | -1.80 | -1.63 | Upgrade
|
| EPS (Diluted) | -0.98 | -1.46 | -1.56 | -1.80 | -1.63 | Upgrade
|
| Free Cash Flow | -67.85 | -49.52 | -57.22 | 7.44 | -15.41 | Upgrade
|
| Free Cash Flow Per Share | -1.47 | -1.33 | -1.78 | 0.25 | -0.56 | Upgrade
|
| Gross Margin | 72.70% | 59.34% | 37.83% | 39.94% | 31.34% | Upgrade
|
| Operating Margin | -114.62% | -165.70% | -236.53% | -369.02% | -565.49% | Upgrade
|
| Profit Margin | -104.74% | -171.37% | -232.44% | -317.44% | -594.03% | Upgrade
|
| Free Cash Flow Margin | -156.85% | -156.49% | -264.22% | 44.26% | -206.00% | Upgrade
|
| EBITDA | -48.99 | -51.81 | -50.62 | -61.69 | -41.62 | Upgrade
|
| EBITDA Margin | -113.25% | -163.74% | -233.78% | - | - | Upgrade
|
| D&A For EBITDA | 0.59 | 0.62 | 0.6 | 0.34 | 0.68 | Upgrade
|
| EBIT | -49.58 | -52.43 | -51.22 | -62.03 | -42.3 | Upgrade
|
| EBIT Margin | -114.62% | -165.70% | -236.53% | - | - | Upgrade
|
Updated Feb 27, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.